Clinical Trial

Phase II Randomized, Open-label, Multicenter Clinical Study Evaluating the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of SHR-2173 Injection in Patients With Primary Membranous Nephropathy

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
To investigate the safety, efficacy, pharmacokinetics, and pharmacodynamics of SHR-2173 injection in patients with primary membranous nephropathy
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-12-04.
Status change: Not Yet Recruiting → Recruiting 2026-01-22
Trial Details
NCT Number NCT07289763
Lead Sponsor Guangdong Hengrui Pharmaceutical Co., Ltd
Conditions Primary Membranous Nephropathy
Enrollment 75 participants
Start Date 2025-12-31
Primary Completion 2027-08 (estimated)
Study Completion 2027-09 (estimated)
Updated on ClinicalTrials.gov 2026-01-26